caspofungin (cancidas) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Caspofungin is an echinocandin antifungal drug, which is approved and is sold under the brand worldwide name cancidas. Caspofungin inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of susceptible Aspergillus species and Candida species. Beta (1,3)-D-glucan is not present in mammalian cells. Cancidas is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients. Also is indicated for the treatment of esophageal candidiasis in adult and pediatric patients and for the treatment of invasive aspergillosis in adult and pediatric patients, but has not been studied as initial therapy for invasive aspergillosis.   NCATS

Chemistry

  • SMILES: CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c4ccc(O)cc4)[C@H](O)CCN
  • InChIKey: JYIKNQVWKBUSNH-OGZDCFRISA-N
  • Mol. Mass: 1093.33
  • ALogP: Missing data
  • ChEMBL Molecules:
    caspofungin  
    caspofungin acetate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$48.9300 - $298.9870
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-[(4r,5s)-5-[(2-aminoethyl)amino]-n(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-l-ornithine]-5-[(3r)-3-hydroxy-l-ornithine]-pneumocandin b0 | (4r,5s)-5-((2-aminoethyl)amino)-n2-(10,12-dimethyltetradecanoyl)-4-hydroxy-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-threo-3-hydroxy-l-ornithyl-trans-3-hydroxy-l-proline cyclic (1->6) disulfide | (4r,5s)-5-((2-aminoethyl)amino)-n(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-threo-3-hydroxy-l-ornithyl-trans-3-hydroxy-l-proline cyclic (6-1)-peptide | cancidas | caspofungin | caspofungin acetate | caspofungin diacetate | caspofungin msd | l 743872 | l 743,872 | l-743872 | l-743,872 | mk 0991 | mk-0991 | mk-991 | pneumocandin b0, 1-((4r,5s)-5-((2-aminoethyl)amino)-n2-((10r,12s)-10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-l-ornithine)-5-((3r)-3-hydroxy-l-ornithine)-

Organizations (64)

Research & Development (55)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (33)

Approved Indications (5)


 

Abdominal Abscess (approved 2001)

Candidemia

Candidiasis (approved 2001)

Invasive Pulmonary Aspergillosis (approved 2001)

Peritonitis (approved 2001)

Experimental Indications - Clinical Trial Phases 1-4 (31)


 

Abdominal Injuries (Phase 2)

Aspergillosis (Phase 4)

Bacterial Infections and Mycoses (Phase 4)

Candidemia (Phase 4)

Candidiasis (Phase 4)

Candidiasis, Invasive (Phase 4)

Candidiasis, Oral (Phase 3)

Critical Illness (Phase 4)

Fever (Phase 2)

Fungemia (Phase 3)

Hematologic Neoplasms (Phase 4)

Hematopoietic Stem Cell Transplantation (Phase 2)

HIV Infections (Phase 2)

Hyperthermia (Phase 3)

Infections (Phase 2)

Invasive Pulmonary Aspergillosis (Phase 4)

Leukemia (Phase 3)

Leukemia, Monocytic, Acute (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myelomonocytic, Acute (Phase 3)

Liver Diseases (Phase 4)

Liver Transplantation (Phase 4)

Lymphoma (Phase 3)

Mycoses (Phase 4)

Myelodysplastic Syndromes (Phase 3)

Neoplasms (Phase 3)

Neutropenia (Phase 3)

Obesity (Phase 4)

Pneumonia, Pneumocystis (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial Organizations: 55

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue